Imaging agents that enable direct visualization and quantification of apoptosis in vivo have great potential value for monitoring chemotherapeutic response as well as for early diagnosis and disease monitoring. We describe here the development of fluorescently labeled activity-based probes (ABPs) that covalently label active caspases in vivo. We used these probes to monitor apoptosis in the thymi of mice treated with dexamethasone as well as in tumor-bearing mice treated with the apoptosis-inducing monoclonal antibody Apomab (Genentech). Caspase ABPs provided direct readouts of the kinetics of apoptosis in live mice, whole organs and tissue extracts. The probes produced a maximum fluorescent signal that could be monitored noninvasively and that coincided with the peak in caspase activity, as measured by gel analysis.
Overall, these studies demonstrate that caspase-specific ABPs have the potential to be used for noninvasive imaging of apoptosis in both preclinical and clinical settings.
As the number of therapies that function by inducing or inhibiting apoptosis continue to grow, imaging tools capable of tracking cell death will become increasingly crucial. Not unexpectedly, strategies for monitoring apoptosis have been developed on the basis of a wide range of surrogate biomarkers. These include specific apoptosis signaling molecules such as the caspases as well as markers of downstream events in the apoptosis cascade.
One commonly used probe of apoptosis, annexin V, is a protein with high affinity for phosphatidylserines exposed during the late stages of apoptosis. Annexin V has been labeled with a number of tags, including fluorochromes 1-3 and radioactive nuclides 4 . Labeled versions of annexin have been used for imaging studies in mouse models of human cancer 1 as well as for positron emission tomography and single photon emission computed tomography-based studies in humans [5] [6] [7] [8] . Although annexin V represents a valuable label of apoptotic cells, its use in humans has had limited success partly as a result of its slow clearance in vivo, which leads to high background signals and incompatibility with radioactive nuclides with short half lives. As an alternative to annexin V, small amphipathic molecules that accumulate in apoptotic cells have been developed 9 . In addition, a radiolabeled analog of g-carboxyglutamic acid ([ 18 F]-ML-10) 10 is currently entering clinical trials for positron emission tomographybased imaging studies of brain metastasis response to treatment (clinical trials NCT00791063, NCT00696943 and NCT00805636). However, the limited information regarding its mode of action makes it difficult to determine the overall applicability of this probe to diverse types of cell death observed in other disease systems.
As direct mediators of the early stages of apoptosis, caspases are obvious targets for molecular imaging probes. Because they are proteases, substrate processing can be used as a readout of activity. Currently, several classes of luminescent 11 , fluorescently quenched 12 or radiolabeled 13 substrate-based probes are in development. Perhaps the biggest challenge for these probes is developing sequences that are specific for caspases. The substrate sequence most commonly used for these probes, Asp-Glu-Val-Asp, although optimal for caspase-3 and caspase-7 (ref. 14) , is also efficiently recognized by several other cysteine proteases, including the cathepsins and legumain 15, 16 . Crossreactivity with cathepsins is especially problematic owing to their high constitutive expression in multiple tissues and organs including the liver, kidney and spleen. As a result, substrate-based reagents containing this or similar selectivity sequences may prove problematic for apoptosis imaging in vivo.
In addition to substrates, several classes of small-molecule inhibitors have been used to label caspase activity in vivo. These include reagents such as WC-II-89, a nonpeptidic competitive inhibitor derived from isatin sulfonamide analogs 17 ; M808, an irreversible inhibitor based on a caspase substrate 17 ; and fluorescently labeled peptide fluoromethyl ketones (FLICA probes) 18, 19 . Although WC-II-89 has been shown to inhibit caspase activity in vitro, it remains difficult to determine its selectivity for caspases in vivo. Likewise, M808 has been shown to have substantial, nonspecific labeling in an in vivo model of cycloheximide-induced hepatocyte apoptosis 20 . The FLICA probes, in contrast, have been used mainly for FACS-based studies of apoptosis and are now commercially available. However, these probes suffer from lack of selectivity 21 and are effective inhibitors of various cathepsins 22 . We have also found that other fluoromethyl ketone-based probes of the caspases yield high levels of background labeling when used in simple in vitro apoptosis systems 15 .
We have previously described the development of irreversible inhibitors and active site probes of the caspases that show both broad and narrow selectivity within this family of proteases 23 . Although we initially found acyloxymethyl ketone (AOMK) probes designed based on our earlier work to be effective labels of caspases in vivo, these reagents showed marked cross-reactivity with cathepsins and legumain 23 . In this study, we identify optimal sequences that show lower legumain reactivity and a complete lack of reactivity toward the cathepsins. Notably, when these optimized probes were labeled with near-infrared fluorescent tags, they allowed caspase labeling to be monitored in vivo by noninvasive imaging methods. Furthermore, addition of a cell-permeable peptide sequence to the probe increased uptake into apoptotic cells, resulting in enhanced overall signal in apoptotic cells and tissues. Overall, these studies show that ABPs that target caspases can be used to track the early stages of apoptosis and that probe signal can be monitored using methods that allow wholebody, noninvasive imaging of apoptosis.
RESULTS

Evaluation and optimization of caspase ABPs
In our past studies, we designed a number of AOMK-based probes that showed efficient labeling of caspases in whole-cell extracts 23 . For our first generation ABP, we converted the most potent and broadspectrum peptide sequence (AB28, containing the amino acid sequence 6-E-8-D) to a fluorescent probe by replacement of the P4 amino acid with a linker labeled with the with the near-infrared fluorescent fluorophore Cy5. We initially tested this probe, AB46-Cy5, in a syngeneic lymphoma model in which tumorigenesis is driven by conditional overexpression of the Myc oncogene 24 ( Supplementary Fig. 1a,b and Supplementary Methods). These initial studies indicated that the probe efficiently labels caspase-3 and caspase-7 but also labels cathepsin B and legumain ( Supplementary  Fig. 1c,d) , consistent with previous studies 15, 16 . To decrease cross-reactivity of AB46-Cy5 with cathepsin B, we made use of our earlier finding that the presence of a proline residue in the P2 position of legumain probes abolishes binding to cathepsin B 16 . Using this information, we developed an ABP containing a Glu-Pro-Asp acyloxymethyl ketone (EPD-AOMK) sequence labeled with the Cy5 fluorophore (AB50-Cy5); this probe showed labeling of caspase-3 and legumain with virtually no detectible cathepsin B labeling ( Supplementary Fig. 1e ). Indirect competition experiments produced similar results ( Supplementary  Fig. 2 ). To decrease the potency of our caspase probes toward legumain, we conducted a screen for P3 amino acids that direct selectivity away from legumain. We identified a series of sequences that enhanced potency toward caspase-3 and away from legumain ( Supplementary  Fig. 3 ). We synthesized a total of 11 inhibitors containing nonnatural amino acids that directed selectivity away from legumain (Supplementary Fig. 4) . From this set of optimized inhibitors, AB53-Cy5, which contained a P3 biphenylalanine, showed the most selectivity toward caspases, with less than one-tenth as much legumain binding relative to AB46-Cy5 or AB50-Cy5 ( Supplementary Fig. 1 ). However, labeling of intact cells indicated that it had relatively poor cell permeability ( Supplementary Fig. 5 ). We, therefore, chose to carry out our in vivo studies with AB50-Cy5.
To enhance the cell permeability of AB50-Cy5, we synthesized a version of the probe containing a Tat peptide. This peptide makes use of multiple positively charged amino acids to carry attached cargo across membranes and has previously been used to increase the cell uptake of caspase substrates 12, 13 . The Tat probe, tAB50-Cy5, differs from AB50-Cy5 in that the Cy5 fluorochrome is moved to a lysine side chain, and the Tat peptide is coupled through a cysteine residue to a maleimide group at the amino terminus of the probe (Fig. 1a) . We also generated control versions of AB50-Cy5 (AB50-Ctrl) and tAB50-Cy5 (tAB50-Ctrl) that contain an amide in place of the reactive (c) Washout studies to monitor probe uptake. Intact Jurkat cells were either treated with the CH11 antibody to Fas (anti-Fas) and then labeled with each probe for the indicated times (direct probe) or pretreated with probes for the indicated times, followed by washout and addition of CH11 (pretreat). Cells were then lysed, and labeled proteins were analyzed by SDS-PAGE followed by scanning for Cy5 fluorescence with a flat-bed laser scanner.
AOMK functional group. As expected, the active probes efficiently labeled recombinant caspase-3, whereas control versions of the probes did not (Fig. 1b) . Note that the addition of the Tat peptide leads to a 2-kDa shift of the protease upon labeling. In addition, we tested all four probes for their ability to label caspases in intact cells treated with an antibody to Fas. We either activated cells by the Fas-specific antibody and directly labeled them with probes or pretreated them with probes and then washed them before activation of apoptosis (Fig. 1c) . These results indicated that only the active probes AB50-Cy5 and tAB50-Cy5 label caspases, and, furthermore, only tAB50-Cy5 showed labeling of caspases after pretreatment and washout (Fig. 1c) . However, we also found that addition of the Tat peptide resulted in a substantial increase in the labeling of legumain. This increase in labeling of a lysosome-resident protease is probably due to uptake of the probe via the endo-lysosomal route before release into the cytosol as has been suggested for similar carrier peptides 25 .
In vivo imaging of caspase activity in apoptotic thymocytes
To show the utility of caspase ABPs for imaging apoptosis, we monitored apoptosis in the CD4 + CD8 + thymocytes of mice treated with dexamethasone 26 . We chose this system because the kinetics of apoptosis have been explored in previous studies using a number of common apoptosis markers including TUNEL 27 and annexin V 28, 29 . We monitored caspase activation in mice treated with dexamethasone for 6, 12 or 24 h (n ¼ 3 for each time point). We injected the AB50-Cy5 and tAB50-Cy5 probes intravenously 2 h before removal of thymi and imaging (Fig. 2a) . After imaging, we processed the tissues and analyzed labeling in total extracts by SDS-PAGE followed by visualization of labeled proteins with a flat-bed laser scanner (Fig. 2a) . This allowed us to biochemically characterize the target proteases labeled by in vivo application of the probe. We confirmed by immunoprecipitation that the probes labeled both caspase-3 and legumain (data not shown). We then quantified total caspase and legumain labeling and compared these values to total fluorescence signals observed in intact thymi (Fig. 2b) . These data indicate that legumain activity is low and remains largely unchanged in the first 12 h after dexamethasone treatment. Caspase-3 activity is observable at 6 h after treatment, peaking at 12 h and then sharply dropping to background levels at 24 h after injection (Fig. 2b) . Notably, the overall trend in amounts of labeled caspases directly correlated with the overall signal observed for intact thymi using the IVIS system, suggesting that the fluorescence observed in whole organs can be used as a direct readout of total probe-labeled proteases. These data also agree with previous studies 27 that showed a peak in TUNEL + thymocyte staining 16 h after dexamethasone treatment followed by a sharp decrease at 18 and 24 h. These observations suggest that caspases are likely to be activated at early time points (that is, 6 h) and, therefore, may serve as effective markers of the early stages of apoptosis.
Comparison of the datasets for the AB50 and tAB50 probes suggested that although the overall trend in fluorescent signals in the intact thymi as well as the labeling patterns of caspases and legumain were the same for both, the overall signal intensity of labeled legumain and caspases as well as fluorescence emitted from intact thymi was increased for the Tat-labeled probe (Fig. 2b) . Quantification of fluorescent signals indicated that peak fluorescence was greater in the tAB50-Cy5-labeled thymi (Fig. 2b) . We did not observe a similar increase in tAB50-Cy5 signal in the samples treated with vehicle, suggesting increased uptake of the probe only into apoptotic cells (Fig. 2b) . In further support of this hypothesis, we analyzed thymocytes from the 12-h time point by flow cytometry ( Supplementary Fig. 6 ). This allowed us to monitor levels of Cy5 fluorescence in both apoptotic (that is, CD4 + CD8 + thymocytes) as well as nonapoptotic cells (that is, CD4 + or CD8 + thymocytes). These data confirmed that dexamethasone treatment specifically induced apoptosis in CD4 + CD8 + cells, as measured by a drop in this cell population over time. Furthermore, the tAB50-Cy5 probe accumulated only in dying cells, and probe-positive cells were also positive for annexin V (Supplementary Fig. 6c ).
To further characterize the properties of our probes in the dexamethasone model, we monitored the uptake of active and control probes into intact thymi at 12 h after treatment with dexamethasone (Fig. 3a) . These data indicated that both AB50-Cy5 and tAB50-Cy5 showed a highly significant accumulation in dexamethasone-treated thymi relative to vehicle-treated tissues (P o 0.003 for AB50-Cy5, P o 0.0005 for tAB50-Cy5). Of note, both control probes showed an accumulation in dexamethasonetreated samples, albeit at lower overall signal compared to the active probe (Fig. 3a) . SDS-PAGE analysis of the total thymus extracts confirmed that the control probes failed to label either legumain or caspases, and these signals were therefore the result of an increase in levels of free probes in dexamethasone-treated samples (Fig. 3b) . Thus, our ability to image apoptosis was enhanced by overall increased probe uptake into apoptotic cells. Finally, histology of thymus tissues showed that signals observed in tissue sections closely matched the signals observed for intact thymi (Fig. 3c) . The signals for both the active and the control Tat probes showed strong nuclear staining of cells and only in dexamethasone-treated tissues (Fig. 3c) . Therefore, we believe that there is considerable uptake of Tat-labeled probes when cells become apoptotic, and this uptake results in nuclear retention of the probes.
Noninvasive imaging of apoptosis in tumors treated with Apomab
In addition to the dexamethasone model, we wanted to evaluate our probes in a more relevant model of human disease. We therefore chose to monitor apoptosis in xenografted human tumor tissues that had been induced to undergo apoptosis by treatment with the monoclonal antibody Apomab. This reagent induces the extrinsic apoptosis pathway by binding death receptor-5 and is currently in phase 2 clinical trials as a chemotherapy agent for lung cancer 30, 31 . We felt this was an ideal model system, because the antibody induces apoptosis in a way that is highly distinct from the dexamethasone-induced intrinsic apoptosis in CD4 + CD8 + thymocytes. As a starting point, we determined the in vivo kinetics of caspase activation in tumor cells in response to Apomab. We treated mice with Apomab, waited 2, 5, 8, 11 and 17 h and then injected AB50-Cy5 and allowed it to circulate for an additional hour. We then imaged whole tumors ex vivo and analyzed caspase labeling by SDS-PAGE (Fig. 4a) . Quantification of total tumor fluorescence, as well as caspase and legumain labeling intensity, indicated that total fluorescent signals in the tumors closely mirrored levels of labeled caspase-3 and caspase-7, as measured by gel analysis (Fig. 4b) . Furthermore, because the overall levels of legumain labeling were constant throughout the time course, this cross-reactivity did not hinder our ability to monitor dynamic changes in caspase activity. Overall, these results indicated that maximum caspase activity occurs 12 h after Apomab treatment.
Because each probe has a different clearance rate, we needed to determine the optimal time for imaging after probe injection. We therefore treated mice with Apomab or vehicle for 12 h, injected each of the active probes and noninvasively monitored tumor fluorescence over a range of time points (Supplementary Fig. 7 ). These data indicated that the Tat-labeled probes show substantially brighter signals but had slow clearance from all tissues, resulting in a low signal-to-background ratio at the early time points ( Supplementary  Fig. 7 ). We observed optimal contrast at 5 h after probe injection. AB50-Cy5, in contrast, cleared rapidly and showed a good signal-tobackground ratio even at the early time points (that is, at 50 min). Thus, we monitored apoptosis in tumors 50 min after injection of AB50-Cy5 and AB50-Ctrl and 5 h after injection of tAB50-Cy5 and tAB50-Ctrl (Fig. 4c) . These images showed specific probe labeling of Apomab-treated tumors, with a high contrast for both tAB50-Cy5 and AB50-Cy5 (4.5-fold and 3.2-fold contrast, respectively; Fig. 4c ).
We also found that the control probes showed some degree of apoptosis-specific uptake into tumors. However, the AB50-Ctrl probe showed substantially weaker signal, and, overall, there was no significant difference in signals of Apomab-treated tumors relative to vehicle-treated tumors (P r 0.27). Notably, tAB50-Ctrl showed nearly identical accumulation in Apomab-treated tumors as tAB50-Cy5 but also produced higher background fluorescence in vehicle-treated tumors (Fig. 4c) . Thus, although the control probes showed some accumulation in apoptotic cells, only the active probes showed a marked contrast between apoptotic and nonapoptotic tumors. Finally, to confirm that the signal that we observed by noninvasive imaging was due to labeling of active caspases, we performed ex vivo imaging of intact tumors (Fig. 5a ) followed by analysis of labeled proteins by SDS-PAGE (Fig. 5b) . The ex vivo images closely matched the images obtained in live mice (Fig. 5a) . In addition, gel analysis showed specific labeling of caspases only in Apomab-treated samples labeled with AB50-Cy5 and tAB50-Cy5 (Fig. 5b) . We also confirmed specific labeling of apoptotic cells by histology of tumor tissues (Fig. 5c) . In agreement with the results obtained for the dexamethasone model (Fig. 3c) , we found that only tumor cells from Apomab treated animals showed probe staining (Fig. 5) . Thus, these data demonstrate that caspase-specific probes can be used to noninvasively monitor apoptosis in tumors treated with chemotherapy agents.
DISCUSSION
The development of reagents that can monitor apoptosis in vivo has potentially great value for monitoring therapeutic efficacy of drugs as well as for diagnosing early stages of diseases involving this key pathway. To address the need for new tools, several strategies have been implemented with mixed success. As the first responders to apoptotic stimuli, caspases are an ideal target for imaging agents for use in both preclinical and clinical applications. Here we described the development of fluorescent activity-based probes and their application in vivo. Starting from a first-generation probe, AB46-Cy5, that shows strong cross-reactivity with both cathepsins and legumain, we were able to improve selectivity of the probes toward caspases and show that they can be used to monitor apoptosis in vivo by both invasive and noninvasive methods. Additionally, because the probes covalently modify target proteases, they allow direct biochemical analysis of the kinetics of apoptosis in vivo.
In addition to finding that the caspase-specific probes can be used to monitor the kinetics of apoptosis in multiple model systems, we also found that control versions of the probes that lack the reactive AOMK functional group show some degree of specific uptake in apoptotic cells. We found that addition of the Tat peptide causes slower clearance and greater uptake into cells. However, we found markedly higher uptake of the Tat control probe compared to the non-Tat control. Histology of tissues from probe-treated mice showed that both active and control Tat probes accumulate in the nucleus, as has been proposed for the Tat peptide in other studies 32 . Although the control probes may still be capable of binding caspases as substrates, we believe that the use of Tat peptides may be beneficial for apoptosis imaging applications. Our results suggest that the non-Tat-labeled probes provide the best direct readout of caspase activity, but that the Tat-labeled probes boost overall specific signal and may therefore be useful for carrying other contrast agents into apoptotic cells.
Although we were able to develop a probe with lower legumain cross-reactivity, the overall degree of selectivity for caspases relative to legumain was modest. We believe that it may be difficult to completely avoid cross-reactivity with legumain. However, labeling of this offtarget protease can potentially be reduced by pretreatment with inhibitors that show exquisite specificity for legumain. For example, preblocking of legumain activity with aza-epoxide containing a P1 asparagine 33 should allow subsequent exclusive labeling of caspases by the AB50 probe series. Alternatively, it may not be necessary to use probes with absolute caspase selectivity for imaging apoptosis in vivo. We found that overall levels of legumain in the dexamethasone model seem to increase at late time points in the apoptosis cascade. This increase may be due to an increase in the overall number of legumainexpressing immune cells that respond to large numbers of dead or dying cells. Thus, probes that label both legumain and caspases may prove to be optimal for monitoring both early (caspase) and late (legumain) stages of apoptosis. Furthermore, the fact that legumain activity remains low and constant during the early stages of caspase activation suggest that probes can still be used to monitor dynamic changes in caspase activity at early time points. Finally, if tags such as Tat provide selective access to apoptotic cells, it may be desirable to have multiple targets that bind probes and lead to their long-term retention within the cell. Although a number of methods have been explored to globally monitor levels of apoptosis, most make use of reporters that cannot be used to directly determine which protease targets are responsible for the production of a fluorescent or radioactive signal. One of the main benefits of the ABPs is their ability to form permanent covalent bonds with target proteases. Thus, signals can be imaged by noninvasive methods, and these signals can then be associated with specific target proteases by biochemical analysis of labeled tissues. In the two examples presented here, we show that overall labeling signals in whole tissues and in live mice correlate with the signal intensity of all labeled proteases in those tissues.
Overall, our data presented show that activity-based probes can be used for direct, noninvasive in vivo imaging of the kinetics of apoptosis in multiple mouse models. For both the dexamethasone and the Apomab systems, caspase activity can be detected at early time points, and it peaks at 12 h. This is in contrast to other markers of apoptosis such as annexin V and TUNEL staining, which serve as markers of the later stages of apoptosis. Thus, caspases are potentially useful markers for apoptosis in vivo, and agents that can be used to monitor dynamic changes in caspase activity are likely to have great value for both preclinical and clinical applications.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
Note: Supplementary information is available on the Nature Medicine website. 
